Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 25

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Neuroendocrine carcinoma

Not recruiting

Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Endocrine ophthalmopathy

Not recruiting

Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AMG 732
  • Sponsor:Amgen Inc.

Diabetic neuropathy+1

Not recruiting

Study of cagrilintide and semaglutide combination versus placebo in people with type 2 diabetes and painful diabetic peripheral neuropathy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not recruiting

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Type 2 diabetes mellitus

Not recruiting

Study of LY3457263 compared to placebo in adults with type 2 diabetes who are taking semaglutide or tirzepatide but have not reached their blood sugar goals

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Not recruiting

Study comparing RO7795081 and semaglutide with placebo in adults with type 2 diabetes mellitus

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:RO7795081
  • Sponsor:F. Hoffmann-La Roche AG

Type 1 diabetes mellitus

Not recruiting

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Adrenoleukodystrophy

Not recruiting

Study of drug interactions between leriglitazone, gemfibrozil, itraconazole, and carbamazepine and food effects in healthy male volunteers for adrenoleukodystrophy treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Carbamazepine
  • Sponsor:Minoryx Therapeutics S.L.

Acromegaly

Not recruiting

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2420
  • Sponsor:Alexion Pharmaceuticals Inc.

Primary hyperaldosteronism

Not recruiting

Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Ertugliflozin and Semaglutide on Heart Health in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Universita Cattolica Del Sacro Cuore

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.